Literature DB >> 26445907

Edoxaban.

Dennis J Cada1, Danial E Baker2, Kyle Ingram3.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The July 2015 monograph topics are ivabradine, dinutuximab, glycopyrronium bromide/indacaterol, patriromer, and idarucizumab. The Safety MUE is on ivabradine.

Entities:  

Year:  2015        PMID： 26445907      PMCID： PMC4589853          DOI： 10.1310/hpj5007-619

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  32 in total

1.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.

Authors:  Dolly A Parasrampuria; Thomas Marbury; Nobujo Matsushima; Shuquan Chen; Prachi K Wickremasingha; Ling He; Victor Dishy; Karen S Brown
Journal:  Thromb Haemost       Date:  2015-01-08       Impact factor: 5.249

3.  Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects.

Authors:  Hamim Zahir; Nobuko Matsushima; Abdel-Baset Halim; Ling He; George Zhang; Frank Lee; Valerie Worland; Jeanne Mendell
Journal:  Thromb Haemost       Date:  2012-05-25       Impact factor: 5.249

Review 4.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

5.  Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans.

Authors:  Mohinder S Bathala; Hiroshi Masumoto; Toshihiro Oguma; Ling He; Chris Lowrie; Jeanne Mendell
Journal:  Drug Metab Dispos       Date:  2012-08-30       Impact factor: 3.922

6.  Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.

Authors:  Meyer M Samama; Satoshi Kunitada; Andŗe Oursin; Francois Depasse; Stan Heptinstall
Journal:  Thromb Res       Date:  2010-10       Impact factor: 3.944

7.  Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination.

Authors:  Jeanne Mendell; Robert J Noveck; Minggao Shi
Journal:  J Cardiovasc Pharmacol       Date:  2012-10       Impact factor: 3.105

8.  The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.

Authors:  Jeanne Mendell; Frank Lee; Shuquan Chen; Valerie Worland; Minggao Shi; Meyer M Samama
Journal:  J Cardiovasc Pharmacol       Date:  2013-08       Impact factor: 3.105

9.  A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin.

Authors:  Bruce S Stambler
Journal:  Int Arch Med       Date:  2013-10-31

10.  Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.

Authors:  Jeanne Mendell; Hamim Zahir; Nobuko Matsushima; Robert Noveck; Frank Lee; Shuquan Chen; George Zhang; Minggao Shi
Journal:  Am J Cardiovasc Drugs       Date:  2013-10       Impact factor: 3.571
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.